Tiantan Bio (600161.SH): Withdrawal of application for registration of recombinant human coagulation factor VIIa for injection.

Zhtng Cijng APP News, Tiantan Bio (600161.SH) announced that Chengdu Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Chengdu Rongsheng"), a subsidiary of Beijing Tiantan Bio Products Co., Ltd., has submitted an application for marketing approval for the "Recombinant Human Coagulation Factor VIIa for Injection" developed by Chengdu Rongsheng to the Drug Evaluation Center (CDE) of the National Medical Products Administration in January 2025, and has obtained the "Acceptance Notice" (Acceptance Number: CXSS2500005). Since the acceptance of the application for marketing approval for this product, Chengdu Rongsheng has been continuously carrying out cooperative evaluation-related work.